Angelini Ventures invests in a $39 million Series A extension round for Therini Bio, advancing treatments for neurodegenerative diseases. This round brings total funding to $75 million.
Angelini Ventures invests in a $39 million Series A extension round for Therini Bio, advancing treatments for neurodegenerative diseases. This round brings total funding to $75 million.
05/14/25, 2:27 PM
Location
sacramentoMoney raised
$39 million
Industry
biotechnology
Round Type
series a
Investors
Sanofi Ventures, Mrl Ventures Fund, Foundation For A Better World, Eli Lilly And Company, Dolby Family Ventures, Dementia Discovery Fund, Sv Health Investors' Biotech Fund, Apollo Health Ventures, Angelini Ventures
Angelini Ventures participates in a $39 million extension of Therini Bio's Series A financing round, aimed at developing fibrin-targeting immunotherapies for neurodegenerative diseases. The investment will fund Phase 1b studies for the lead candidate, THN391, targeting Alzheimer's Disease and Diabetic Macular Edema. The total raised in this Series A round now stands at $75 million, with participation from top-tier investors including Apollo Health Ventures and SV Health Investors.
Company Info
Location
sacramento, california, united states
Additional Info
Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.